BioMed Research International / 2015 / Article / Tab 1

Review Article

Prevention of Nausea and Vomiting in Patients Undergoing Oral Anticancer Therapies for Solid Tumors

Table 1

Emetogenic potential of oral antineoplastic agents most used in solid tumors (based on MASCC and ESMO guidelines 2010).

MASCC and ESMO guidelines 2010
Degree of emetogenicity (incidence)Agent

High (>90%)Hexamethylmelamine
Procarbazine

Moderate (30–90%)Cyclophosphamide
Temozolomide
Vinorelbine
Imatinib

Low (10–30%)Capecitabine
Etoposide
Sunitinib
Everolimus
Lapatinib

Minimal (<10%)Methotrexate
Gefitinib
Erlotinib
Sorafenib